Clinical Trials Logo

X-linked Myotubular Myopathy clinical trials

View clinical trials related to X-linked Myotubular Myopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02704273 Completed - Clinical trials for X-linked Myotubular Myopathy

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

INCEPTUS
Start date: July 2016
Phase:
Study type: Observational

This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.

NCT ID: NCT02453152 Completed - Clinical trials for X-linked Myotubular Myopathy

Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)

Start date: October 2015
Phase:
Study type: Observational

This study is a longitudinal study evaluating the severity and progression of respiratory muscle function in patients with X-Linked Myotubular Myopathy (XLMTM) aged 0-14.

NCT ID: NCT01840657 Completed - Clinical trials for X-linked Myotubular Myopathy

Myotubular Myopathy Event Study

MTMES
Start date: April 2013
Phase: N/A
Study type: Observational

X-Linked myotubular myopathy (XLMTM), a form of centronuclear myopathy (CNM) is the result of a mutation in the MTM1 (myotubularin) gene which leads to altered myotubularin. Myotubularin is essential for optimum muscle function. To date, over 100 mutations have been described resulting in a range of disease onset and symptom severity. The early onset form presents with neonatal hypotonia, muscle weakness, respiratory distress and an ongoing requirement for continuous ventilatory support with the inability to maintain a sitting position once placed. Males with both later onset and milder symptoms usually do not require ongoing ventilatory support, achieve a higher maximal motor function with ability to sit when placed and even walk, and have improved survival rates. Males with XLMTM may experience complications (events) at birth and throughout their lifetime. The goal of the study is to identify the number of events over twelve months in males with genetically confirmed XLMTM. Parents or affected individuals over the age of 18 years who are able to access telephone will provide answers to an established event survey to evaluate the frequency and types of events. Emergency department, hospital admissions and mortality will be confirmed by obtaining medical reports. The investigators hypothesize that there will be no association between the frequency of events and markers of clinical severity including the need for ventilatory support at birth, current level of ventilatory support (no support, support less than 12 hours, support more than 12 hours) and current motor function (walking, sitting without support, inability to sit without support).